Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -1.13 Million | -137.16 Thousand | -451.5 Thousand | -1.06 Million |
| Net Income | - | - | -651.55 Thousand | 779.12 Thousand | -552.74 Thousand | -2.09 Million |
| Depreciation & Amortization | - | - | 1817.00 | 58.17 Thousand | 63.2 Thousand | 66.08 Thousand |
| Deferred income taxes | - | - | - | - | - | 179.22 Thousand |
| Stock-based compensation | - | - | - | - | 80 Thousand | 803.00 |
| Change in working capital | - | - | 179.64 Thousand | -567.55 Thousand | 617.65 Thousand | 806.88 Thousand |
| Other non-cash items | - | - | -662.92 Thousand | -406.91 Thousand | -579.61 Thousand | -18.88 Thousand |
| Investing Cash Flow | - | - | -3433.00 | - | 650 Thousand | - |
| Investments in PPE | - | - | -3433.00 | - | - | - |
| Acquisitions | - | - | - | - | 650 Thousand | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | 650 Thousand | - |
| Financing Cash Flow | - | - | 1.52 Million | 55.44 Thousand | -165.37 Thousand | 180.98 Thousand |
| Debt repayment | - | - | -204.52 Thousand | -99.76 Thousand | -194.61 Thousand | -30.52 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 600 Thousand | - | - | - |
| Other Financing Activities | - | - | 1.12 Million | 155.2 Thousand | 29.24 Thousand | 211.5 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | -153.52 Thousand | 77.51 Thousand | -12.26 Thousand | 197.15 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | 333.16 Thousand | -645.06 Thousand | 629.91 Thousand | 609.73 Thousand |
| Cash at beginning of period | - | 386.02 Thousand | 400.00 | 82.11 Thousand | 48.98 Thousand | 930.39 Thousand |
| Cash at end of period | - | 386.02 Thousand | 386.02 Thousand | 400.00 | 82.11 Thousand | 48.98 Thousand |
| Capital Expenditure | - | - | -3433.00 | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 385.62 Thousand | -81.71 Thousand | 33.12 Thousand | -881.4 Thousand |
| Free Cash Flow | - | - | -1.13 Million | -137.16 Thousand | -451.5 Thousand | -1.06 Million |
| Breakdown | 2022 FY | 2021 FY | 2020 Q4 | 2020 FY | 2020 Q3 | 2020 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | -489.5 Thousand | -651.55 Thousand | -401.4 Thousand | 408.17 Thousand |
| Depreciation & Amortization | - | - | 656.00 | 1817.00 | 370.00 | 370.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 219.96 Thousand | 179.64 Thousand | -151.57 Thousand | 36.72 Thousand |
| Other non-cash items | - | - | -68.97 Thousand | -662.92 Thousand | 72.8 Thousand | -666.75 Thousand |
| Investing Cash Flow | - | - | -4.00 | -3433.00 | -3429.00 | - |
| Investments in PPE | - | - | -4.00 | -3433.00 | -3429.00 | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | -57.67 Thousand | 1.52 Million | -47.67 Thousand | 1.53 Million |
| Debt repayment | - | - | -35.37 Thousand | -204.52 Thousand | -12.32 Thousand | -37.07 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 600 Thousand | 600 Thousand | - | - |
| Other Financing Activities | - | - | -622.3 Thousand | 1.12 Million | -47.67 Thousand | 1.49 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | 151.65 Thousand | -153.52 Thousand | -226.47 Thousand | -151.62 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | 68.3 Thousand | 333.16 Thousand | 74.9 Thousand | 188.34 Thousand |
| Cash at beginning of period | - | 386.02 Thousand | 781.57 Thousand | 400.00 | 1.31 Million | 2926.00 |
| Cash at end of period | - | 386.02 Thousand | 386.02 Thousand | 386.02 Thousand | 781.57 Thousand | 1.31 Million |
| Capital Expenditure | - | - | -4.00 | -3433.00 | -3429.00 | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | -395.54 Thousand | 385.62 Thousand | -530.9 Thousand | 1.3 Million |
| Free Cash Flow | - | - | -337.86 Thousand | -1.13 Million | -483.22 Thousand | -221.48 Thousand |
BYD
MUX
AILLM
HBGRF
002017
HIPH